Wyeth

Pfizer Corporation

Jason Shaoyun Xiang

Steve Yikkai Tam

Phaik-Eng Sum

David Brian How

Joshua James Sabatini

Tarek Suhayl Mansour

Lihren Chen

Yonghan Hu

Thomas Saltmarsh Rush, Iii

Jerauld S Skotnicki

Wei Li

Neal Green

Eric Feyfant

Elisabeth Ann Morris

Matthew Douglas Vera

Darrin William Hopper

Jianchang Li

Audrey Molina Davies

Steve Yik-Kai Tam

Gary Paul Stack

Jeremy Ian Levin

Derek Cecil Cole

Joseph Walter Strohbach

Ariamala Gopalsamy

Eddine Saiah

John Paul Mathias

Douglas Wilson

Li Huang Xing

Jinbo Lee

Xiaolun Wang

Frank Eldridge Lovering

Zhao-Kui Wan

Xuemei Du

John C McKew

Agustin Casimiro-Garcia

Andrew Christopher Flick

Katy Evangelia Georgiadis

Eva Deanna Binnun

Steven J Kirincich

Huan-Qiu Li

Joseph Walter Strobach

Manus Ipek

Vipin Suri

Yuchuan Wu

Jun Jun Wu

Rajeev Hotchandani

Sonya Glasson

Jeffrey Scott Condon

Compounds, pharmaceutically acceptable salts thereof, are disclosed wherein the compounds have the structure of as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

Heterocyclic compounds as inhibitors of Vanin-1 enzyme

The present invention relates to modulators of metalloproteinase activity.

Glutamate aggrecanase inhibitors

The present invention relates to biaryl sulfonamides and their use as, for example, metalloproteinase inhibitors.

Biaryl sulfonamides and methods for using same

This invention relates to inhibiting 11&#x3b2;HSD1.

11-beta HSD1 inhibitors

The present invention relates to methods of treating ADAMTS-5-associated diseases and particularly osteoarthritis comprising administering an agent capable of modulating ADMATS-5 activity to a subject afflicted with the disease. The agent is preferably a biaryl sulfonamide compound. The invention is based, in part, on the discovery that transgenic animals that do not express functional ADAMTS-5 show a reduction in the degree of osteoarthritis after the induction of osteoarthritis as compared to WT animals. Furthermore, the ADAMTS-5 transgenic animals have reduced aggrecanase activity in articular tissue as compared to WT animals. These animals are good models for ADAMTS-5-associated diseases, and for screening of drugs useful in the treatment and/or prevention of these diseases. There are no other animal models in which the deletion of the activity of a single gene is capable of abrogating the course of osteoarthritis. Accordingly, these animals also show that osteoarthritis can be prevented and/or treated by administering to a subject an ADAMTS-5 inhibitory agent and particularly an agent capable of inhibiting the aggrecanase activity of ADAMTS-5.

Method for treating ADAMTS-5-associated disease

The present invention provides a compound of formula I and the use thereof for the immunotherapeutic treatment of transplant rejection, autoimmune disease or graft vs. host disease.

Dihydrodipyrazolopyridinone inhibitors of B7-1

The present invention provides a compound of formula I and the use thereof for the immunotherapeutic treatment of transplant rejection or autoimmune disease.

Dihydrodipyrazolopyridinylbenzamide and -sulfonamide inhibitors of B7-1

Growing community of inventors

Winchester, MA, United States of America

Jason Shaoyun Xiang